The Enterprise Vascular Reconstruction Device and Delivery System (Cordis; the Enterprise stent) was approved for use in conjunction with coiling of wide-necked aneurysms in 2007.

     No published long-term aneurysm occlusion or complication data exists for the Enterprise system.

     Two-hundred and twenty-nine patients with 229 aneurysms, 32 of which were ruptured aneurysms, were included in the study.

     An eight-center registry was created to evaluate large volume data on the delayed safety and efficacy of the Enterprise stent system. Pooled data were compiled for consecutive patients undergoing Enterprise stent-assisted coiling at each institution prior to May 2009.

     Mean clinical and angiographic follow-up was 619.6 ± 26.4 days and 655.7 ± 25.2 days, respectively. Mean aneurysm size was 9.2 ± 0.4 mm. Fifty-nine percent of patients demonstrated 100% coil obliteration and 81% had 90% or higher occlusion at last follow-up angiography. A total of 19 patients (8.3%) underwent re-treatment of their aneurysms during the follow-up period. Angiographic in-stent stenosis was seen in 3.4% and thromboembolic events occurred in 4.4%. Overall, 91% of patients who underwent Enterprise-assisted coiling had a modified Rankin Score (mRS) of 2 or less at last follow-up. Poor mRS was strongly associated with rupture status (p < 0.001).

     This is a retrospective study.

     The Enterprise stent system is an effective, safe, and durable treatment for intracranial aneurysms when used in conjunction with coiling.